BuzzSparks.org

ARCH Venture Partners


ARCH invests primarily in companies co-founded with leading scientists and entrepreneurs, concentrating on bringing to market innovations in life sciences, physical sciences, and information technology. They enjoy special recognition as a leader in...

Founded in 1986
Homepage:

ARCH Midwest

60631 8725 W. Higgins Road, Suite 290

Chicago
USA IL

Phone: 773 380 6600

Updated on Jun 3, 2009
ARCH Venture Partners at CrunchBase
Robert T. Nelsen Co-founder and Managing Director
Clinton W. Bybee Co-founder and Managing Director
Keith L. Crandell Co-founder and Managing Director
Paul Thurk Partner
Steven Gillis Managing Director
Kristina Burrow Partner
Past

April, 2013

ARCH Venture Partners invested $30M in Syros Pharmaceuticals as a Series A round

ARCH Venture Partners invested $14.5M in AgBiome as a Series A round

March, 2013

ARCH Venture Partners invested $8M in Theraclone Sciences as a Series B round

November, 2012

ARCH Venture Partners invested $18.5M in Quanterix as a Series C round

September, 2012

ARCH Venture Partners invested $8.1M in 908 Devices as a Series A round

July, 2012

ARCH Venture Partners invested $30M in Siluria Technologies as a Series C round

ARCH Venture Partners invested $21M in Impinj as unattributed round

ARCH Venture Partners invested $60M in bluebird bio as a Series D round

ARCH Venture Partners invested $38.5M in Chiasma as a Series D round

January, 2012

ARCH Venture Partners invested $7.5M in Semprius as unattributed round

December, 2011

ARCH Venture Partners invested $6M in Groove Biopharma as a Series B round

November, 2011

ARCH Venture Partners invested $78M in Agios Pharmaceuticals as a Series C round

September, 2011

ARCH Venture Partners invested $20M in Siluria Technologies as a Series B round

ARCH Venture Partners invested $37.4M in Kythera Biopharmaceuticals as a Series D round

August, 2011

ARCH Venture Partners invested $15.2M in Shocking Technologies as a Series C round

ARCH Venture Partners invested $14M in Pulmatrix as a Series B round

ARCH Venture Partners invested $2.1M in Oncofactor Corporation as a Series A round

June, 2011

ARCH Venture Partners invested $20M in Semprius as a Series C round

ARCH Venture Partners invested $36M in Sorbent Therapeutics as a Series B round

April, 2011

ARCH Venture Partners invested $30M in bluebird bio as unattributed round

January, 2011

ARCH Venture Partners invested $7M in Univa as unattributed round

ARCH Venture Partners invested $4.4M in Acylin Therapeutics as a Series A round

October, 2010

ARCH Venture Partners invested unknown amount in Kilimanjaro Energy as a Series A round

ARCH Venture Partners invested $13.3M in Siluria Technologies as unattributed round

September, 2010

ARCH Venture Partners invested $21.8M in Sorbent Therapeutics as a Series B round

August, 2010

ARCH Venture Partners invested $4M in Crystal IS as a Series B round

ARCH Venture Partners invested $5M in Ciespace as a Series A round

June, 2010

ARCH Venture Partners invested $12.4M in Bind Biosciences as a Series C round

ARCH Venture Partners invested $3.5M in Adesto Technologies as unattributed round

April, 2010

ARCH Venture Partners invested $3.9M in Mirina as a Series A round

ARCH Venture Partners invested $56M in Achaogen as a Series C round

March, 2010

ARCH Venture Partners invested $1.5M in Theraclone Sciences as unattributed round

February, 2010

ARCH Venture Partners invested $8M in Shocking Technologies as a Series B round

January, 2010

ARCH Venture Partners invested $51.6M in VentiRx Pharmaceuticals as a Series A round

ARCH Venture Partners invested $18M in Innovalight as a Series D round

November, 2009

ARCH Venture Partners invested $25M in Receptos as a Series A round

ARCH Venture Partners invested $30M in Fate Therapeutics as a Series B round

ARCH Venture Partners invested $30.2M in Pulmatrix as a Series B round

ARCH Venture Partners invested $14.5M in Cambrios Technologies as a Series D round

October, 2009

ARCH Venture Partners invested $15M in Innovalight as unattributed round

August, 2009

ARCH Venture Partners invested $10M in Shocking Technologies as a Series B round

July, 2009

ARCH Venture Partners invested $15M in Limerick BioPharma as a Series C round

June, 2009

ARCH Venture Partners invested $6.4M in Semprius as a Series B round

May, 2009

ARCH Venture Partners invested $12M in Elixir Pharmaceuticals as a Series D round

ARCH Venture Partners invested $36M in Lycera as a Series A round

January, 2009

ARCH Venture Partners invested $7M in Qwell Pharmaceuticals as a Series A round

September, 2008

ARCH Venture Partners invested $35M in Sapphire Energy as a Series D round

June, 2008

ARCH Venture Partners invested $15.2M in Limerick BioPharma as unattributed round

May, 2008

ARCH Venture Partners invested $50M in Sapphire Energy as a Series C round

ARCH Venture Partners invested $30M in Kythera Biopharmaceuticals as a Series C round

ARCH Venture Partners invested $8M in Univa UD as a Series B round

February, 2008

ARCH Venture Partners invested $19M in PhaseRx as a Series A round

ARCH Venture Partners invested $10M in KOTURA as a Series C round

ARCH Venture Partners invested $7M in MediaPhy as unattributed round

November, 2007

ARCH Venture Partners invested $12M in Fate Therapeutics as a Series A round

October, 2007

ARCH Venture Partners invested $30M in Allozyne as a Series B round

August, 2007

ARCH Venture Partners invested $52M in Xtera Communications as unattributed round

July, 2007

ARCH Venture Partners invested $4.1M in Semprius as a Series A round

April, 2007

ARCH Venture Partners invested $7M in Shocking Technologies as a Series A round

March, 2007

ARCH Venture Partners invested $19M in Impinj as a Series E round

February, 2007

ARCH Venture Partners invested $63M in Omeros as a Series E round

January, 2007

ARCH Venture Partners invested $35.7M in Variation Biotechnologies as a Series A round

November, 2006

ARCH Venture Partners invested $46M in Elixir Pharmaceuticals as a Series C round

ARCH Venture Partners invested $44M in Chiasma as a Series C round

October, 2006

ARCH Venture Partners invested $6.3M in Aveso as a Series B round

ARCH Venture Partners invested $26M in Achaogen as a Series B round

August, 2006

ARCH Venture Partners invested $10.6M in Crystal IS as a Series B round

July, 2006

ARCH Venture Partners invested $30M in Kythera Biopharmaceuticals as a Series B round

ARCH Venture Partners invested $25M in AmberWave as a Series E round

June, 2006

ARCH Venture Partners invested $21.8M in Nitronex as unattributed round

ARCH Venture Partners invested $55M in VLST Corporation as a Series B round

December, 2005

ARCH Venture Partners invested $26.5M in Impinj as unattributed round

ARCH Venture Partners invested $3.5M in Allozyne as a Series A round

November, 2005

ARCH Venture Partners invested $41.5M in nanosys as a Series D round

September, 2005

ARCH Venture Partners invested $13M in KOTURA as a Series B round

August, 2005

ARCH Venture Partners invested $8M in Univa UD as a Series A round

February, 2005

ARCH Venture Partners invested $12M in Cambrios Technologies as a Series B round

January, 2005

ARCH Venture Partners invested $10M in Ahura Scientific as a Series B round

May, 2004

ARCH Venture Partners invested $15M in Ensemble Discovery as a Series A round

1986

ARCH Venture Partners was founded in 1986